Drugs Containing Excipient (Inactive Ingredient) BERGAMOT ORANGE

Generic drugs containing BERGAMOT ORANGE excipient

Company	Ingredient	NDC	Excipient
Incredible Products SA de CV	minoxidil	71761-260	BERGAMOT ORANGE

Bergamot Orange Pharmaceutical Excipient Market: Dynamics, Supply Risk, and Financial Trajectory

Last updated: August 27, 2026

Bergamot orange is a niche pharmaceutical excipient and flavoring ingredient rather than a standardized, high-volume excipient category. Commercial use is concentrated in oral medicines, nutraceuticals, traditional medicines, and personal-care products. The market has attractive pricing for traceable, low-furanocoumarin material, but pharmaceutical demand remains limited by regulatory qualification, phototoxicity concerns, compositional variability, and the absence of a broad pharmacopeial standard.

Public companies do not generally report bergamot-derived pharmaceutical revenue separately. Financial analysis therefore relies on proxy indicators: bergamot oil prices, citrus harvest conditions, essential-oil demand, flavor-and-fragrance revenue, nutraceutical adoption, and costs associated with testing and qualification.

What is bergamot orange when used as a pharmaceutical excipient?

Bergamot orange is the fruit of Citrus bergamia, a citrus species cultivated primarily in Calabria, Italy. Pharmaceutical and health-product applications may use bergamot peel oil, fruit extract, juice-derived solids, or purified fractions.

The material can function as:

• A flavoring agent in oral tablets, capsules, syrups, and liquid formulations.
• A fragrance component in topical products.
• A botanical active or supporting ingredient in nutraceutical products.
• A source of citrus-derived aromatic compounds.

Bergamot should not be treated as a single chemically uniform excipient. Its composition depends on the plant part, extraction method, geographic origin, harvest period, storage, and treatment to remove furanocoumarins.

The principal commercial constituents of bergamot peel oil include limonene, linalyl acetate, linalool, and other volatile compounds. Bergapten and bergamottin are important risk-control compounds because certain furanocoumarins can cause phototoxic reactions and may affect drug-metabolizing enzymes.[1][2]

What is the market size for bergamot orange pharmaceutical excipients?

No separately reported global market size exists for bergamot orange as a pharmaceutical excipient. Market reports usually place bergamot within broader categories such as:

• Citrus essential oils.
• Natural flavors.
• Botanical extracts.
• Pharmaceutical flavoring agents.
• Nutraceutical ingredients.
• Fragrance ingredients.

This limits the reliability of standalone revenue estimates. The pharmaceutical excipient portion is likely small relative to fragrance, cosmetics, food flavoring, and dietary supplements.

A practical market model divides bergamot demand into four segments:

Segment	Relative commercial importance	Primary buying criteria
Fragrance and personal care	High	Aroma profile, consistency, price
Food and beverage flavoring	High	Regulatory compliance, sensory profile, cost
Nutraceuticals	Moderate	Standardization, clinical positioning, contaminant control
Pharmaceutical excipients	Low but higher value per kilogram	GMP documentation, batch consistency, toxicology, supply continuity

Pharmaceutical-grade material can command a premium over commodity bergamot oil because buyers may require identity testing, pesticide analysis, residual-solvent testing, microbial limits, heavy-metal testing, furanocoumarin quantification, allergen declarations, and change-control commitments.

How is the bergamot orange market developing financially?

The financial trajectory is best characterized as a premium niche market with volume constraints.

Revenue growth is likely to come from:

1. Increased use of natural flavor systems in oral medicines and supplements.
2. Expansion of standardized bergamot polyphenolic fractions in cardiovascular and metabolic-health products.
3. Demand for traceable, low-phototoxicity or furanocoumarin-controlled ingredients.
4. Growth in clean-label and botanical formulations.
5. Higher qualification requirements that favor established suppliers.

Margin pressure comes from:

• Crop concentration in Calabria.
• Weather-related yield volatility.
• Citrus disease and agricultural input costs.
• Competition from synthetic aroma chemicals.
• Substitution by lemon, orange, grapefruit, or mandarin flavors.
• Small pharmaceutical batch sizes.
• Long regulatory qualification cycles.
• The cost of maintaining multiple extraction and purification specifications.

The highest-margin products are not necessarily conventional bergamot oils. They are likely to be standardized extracts, low-furanocoumarin oils, encapsulated flavors, and custom pharmaceutical flavor systems with validated specifications.

Who supplies bergamot orange pharmaceutical-grade material?

The supply chain includes citrus growers, primary oil processors, botanical extract manufacturers, flavor houses, and pharmaceutical excipient distributors.

Relevant global supplier groups include:

• Italian bergamot oil processors and Calabria-based agricultural networks.
• International flavor-and-fragrance companies such as Givaudan, dsm-firmenich, Robertet, Symrise, and IFF.
• Specialty natural-ingredient suppliers and distributors.
• Contract manufacturers producing standardized bergamot extracts for nutraceutical brands.
• Pharmaceutical excipient distributors that source material from qualified botanical processors.

The large flavor-and-fragrance companies may have greater purchasing power and technical resources than pharmaceutical excipient specialists. This can create competition for raw material during poor harvests.

Pharmaceutical buyers typically prefer suppliers that can provide:

• A defined botanical source.
• A stable certificate of analysis.
• Residual-pesticide and contaminant controls.
• A documented extraction process.
• Batch-to-batch chemical fingerprinting.
• GMP or food-grade quality systems appropriate to the intended use.
• Change-notification procedures.
• Long-term supply commitments.

What regulatory status does bergamot orange have with the FDA?

Bergamot-derived material may be used as a flavoring or botanical ingredient, but regulatory treatment depends on the precise substance, intended use, dosage, route of administration, and labeling.

For oral pharmaceutical products, the relevant FDA pathway is generally the inactive-ingredient framework. Drug manufacturers must establish that the proposed level and route are acceptable. The FDA Inactive Ingredient Database is the principal reference for previously used inactive ingredients, although an individual bergamot preparation may not be interchangeable with another preparation merely because both are labeled "bergamot."[3]

Key regulatory distinctions include:

Material	Regulatory issue
Bergamot peel oil	Flavoring, phototoxicity, composition, allergen and impurity control
Furanocoumarin-reduced bergamot oil	Processing validation and residual-compound limits
Bergamot fruit extract	Botanical identity, marker compounds, solvent and contaminant control
Bergamot polyphenolic fraction	Standardization, clinical substantiation, drug-interaction assessment
Bergamot flavor blend	Mixture composition and proprietary formulation control

Food-use authorization does not automatically establish pharmaceutical acceptability. A flavoring status under food regulations is not equivalent to an FDA-approved pharmaceutical excipient designation.

The European Union applies its flavoring framework under Regulation (EC) No. 1334/2008, while botanical products may also be subject to national medicinal-product and supplement rules.[4] The regulatory position therefore varies by market and by product claim.

What safety risks affect bergamot orange excipient adoption?

Phototoxicity is the most important technical risk associated with bergamot peel oil. Furocoumarins can increase skin sensitivity to ultraviolet radiation. This issue is particularly relevant to topical products and to oral products that contain comparatively high botanical doses.

Other controls include:

• Potential drug-metabolism interactions involving bergamottin and related constituents.
• Oxidation of volatile oil components during storage.
• Allergen labeling.
• Pesticide residues.
• Adulteration with cheaper citrus oils.
• Microbial contamination in aqueous or nonvolatile extracts.
• Residual solvents from extraction.
• Variation in marker compounds.
• Stability loss caused by oxygen, light, or heat.

For oral medicines, the phototoxicity risk may be less direct than in topical formulations, but the overall toxicological profile still requires assessment at the proposed daily exposure. A low-furanocoumarin specification can reduce risk but adds processing cost and analytical requirements.

What patents protect bergamot orange pharmaceutical excipients?

Bergamot itself is not protected by a single dominant pharmaceutical patent estate. Patent activity is more likely to cover:

• Standardized bergamot extracts.
• Polyphenolic fractions.
• Specific ratios of flavonoids.
• Methods for reducing furanocoumarins.
• Encapsulation and controlled-release systems.
• Combination products for cholesterol or metabolic disorders.
• Cosmetic compositions containing bergamot derivatives.
• Extraction and purification processes.

Patent value depends on claim scope and jurisdiction. A patent claiming "bergamot extract" broadly may face prior-art and enablement challenges if the extract is not chemically defined. Claims tied to quantified markers, specific extraction parameters, or validated biological activity can be stronger.

No Orange Book listing is expected for bergamot as an excipient. Orange Book patents generally relate to approved drug products, active ingredients, formulations, and methods of use, not stand-alone excipient commodities.[5]

Are there Paragraph IV challenges or biosimilar risks for bergamot orange?

Paragraph IV litigation and biosimilar competition are not relevant to bergamot as a pharmaceutical excipient.

A generic drug applicant could challenge a patent covering a finished dosage form that uses bergamot, a bergamot-containing formulation, or a method of treatment. Such a challenge would target the drug product patent, not bergamot as a raw material.

Biosimilar risk is also not applicable because bergamot is a small-molecule botanical ingredient, not a biologic reference product. Competitive risk instead comes from:

• Alternative citrus flavors.
• Synthetic flavor chemicals.
• Other botanical extracts.
• Furanocoumarin-free citrus fractions.
• Proprietary flavor blends.
• Reformulation using non-citrus masking agents.

What formulation patents may protect bergamot-containing medicines?

Potential formulation protection may cover:

• Taste-masked tablets or orally disintegrating tablets.
• Lipid-based or self-emulsifying delivery systems.
• Microencapsulated bergamot oil.
• Enteric-coated capsules.
• Combination supplements with statins, berberine, or other metabolic ingredients.
• Topical products with reduced phototoxicity.
• Controlled-release botanical formulations.
• Stabilized liquids using antioxidants or oxygen-impermeable packaging.

The commercial strength of these patents depends on whether the claim protects a difficult-to-reproduce delivery system or merely identifies bergamot as one optional flavor. Narrow claims with defined particle size, encapsulation efficiency, marker-compound content, or release profile are more defensible than generic ingredient lists.

How does bergamot compare with competing pharmaceutical flavoring ingredients?

Ingredient	Main advantage	Main limitation	Pharmaceutical positioning
Bergamot	Distinctive citrus-floral taste and premium natural profile	Phototoxicity and variable composition	Niche oral flavor and botanical ingredient
Lemon oil	Familiar citrus profile and broad availability	Oxidation and allergen concerns	Broad oral formulation use
Orange oil	Low-cost, familiar flavor	Less differentiated	High-volume flavoring
Peppermint oil	Strong masking and cooling effect	Potential gastrointestinal intolerance	Common oral and digestive products
Grapefruit flavor	Strong citrus identity	Drug-interaction and furanocoumarin concerns	More restricted in sensitive products
Synthetic citrus flavor	Consistent and inexpensive	Lower natural-positioning value	Cost-sensitive formulations

Bergamot is more differentiated than orange or lemon but has a narrower regulatory and supply profile. It competes on sensory identity and botanical positioning rather than cost.

What manufacturing and intellectual-property barriers exist?

The primary barriers are process and quality barriers, not basic patent barriers.

Manufacturers must control:

1. Botanical authentication.
2. Harvest and geographic traceability.
3. Peel processing and oil recovery.
4. Furanocoumarin content.
5. Oxidation and storage conditions.
6. Adulteration detection.
7. Batch-to-batch flavor consistency.
8. Extraction yield.
9. Stability in the finished dosage form.

Process know-how can create meaningful commercial protection even where patent claims are weak. Suppliers with validated low-furanocoumarin processing, reliable Calabria sourcing, and pharmaceutical-quality documentation may retain customers through qualification costs and switching friction.

What licensing deals and partnerships affect the market?

Publicly disclosed licensing transactions dedicated solely to bergamot as a pharmaceutical excipient are limited. Commercial partnerships are more likely to involve:

• Botanical extract brands licensing standardized compositions.
• Flavor houses supplying proprietary flavor systems.
• Contract manufacturers producing nutraceutical formulations.
• Agricultural cooperatives supporting traceable sourcing.
• Pharmaceutical companies qualifying a supplier under a long-term supply agreement.

The absence of large disclosed licensing deals indicates that bergamot is not currently a major standalone pharmaceutical platform. Its commercial value is usually embedded in a broader formulation, botanical-extract, flavor, or consumer-health agreement.

What generic entry risks exist for bergamot-containing products?

Generic entry risk is generally high for products where bergamot is used only as a flavor. A generic manufacturer can usually substitute another citrus flavor unless the reference product has a protected formulation or a clinically relevant standardized extract.

Risk is lower when the product depends on:

• A patented standardized composition.
• A proprietary low-furanocoumarin process.
• A validated taste-masking system.
• A specific delivery technology.
• A narrow marker-compound profile.
• Clinical data tied to a defined bergamot fraction.

For prescription products, the principal exposure is formulation substitution rather than raw-material exclusivity. For over-the-counter and nutraceutical products, brand, sensory profile, sourcing claims, and clinical substantiation may be more important than patent protection.

What is the geographic coverage of the bergamot orange supply chain?

Italy, particularly Calabria, is the central origin for premium bergamot oil. Downstream processing and distribution are global, with major activity in Europe, North America, and Asia.

Geographic exposure affects:

• Crop availability.
• Export logistics.
• Certification requirements.
• Currency costs.
• Local agricultural regulation.
• Traceability claims.
• Supplier concentration.

A pharmaceutical manufacturer relying on a single Calabria-origin supplier faces higher continuity risk than one using a qualified multi-origin strategy. Multi-origin sourcing can reduce supply risk but may change the sensory and chemical profile, requiring regulatory and formulation requalification.

What is the outlook for bergamot orange pharmaceutical excipients?

The base case is moderate value growth from a small base, driven by premium natural formulations rather than pharmaceutical volume expansion.

Time horizon	Expected market direction	Main driver
Near term	Stable to modest growth	Oral flavoring and supplement demand
Medium term	Premiumization	Standardized and low-furanocoumarin products
Longer term	Selective expansion	Botanical medicines, delivery systems, and traceable sourcing

The market is unlikely to become a major standalone pharmaceutical-excipient category without a new approved medicine or widely adopted standardized botanical product. The strongest commercial opportunities are in high-specification ingredients, custom formulations, and products that monetize traceability and compositional control.

Key Takeaways

• Bergamot orange is a niche botanical flavoring and excipient, not a major standardized pharmaceutical-excipient class.
• Pharmaceutical revenue is not separately disclosed, so market sizing requires proxy analysis.
• The highest-value applications involve standardized extracts, low-furanocoumarin oils, encapsulation, and qualified oral formulations.
• Calabria-centered sourcing creates geographic and crop-yield concentration risk.
• Phototoxicity, drug-interaction potential, oxidation, and compositional variability are the main technical barriers.
• Bergamot has no conventional Orange Book, Paragraph IV, or biosimilar exposure as a stand-alone excipient.
• Patent value is concentrated in standardized compositions, extraction processes, and delivery systems.
• Generic risk is high when bergamot is only a replaceable flavor and lower when it is tied to a defined formulation or clinically supported extract.
• The likely financial trajectory is premium niche growth, not mass-market pharmaceutical expansion.

FAQs About Bergamot Orange as a Pharmaceutical Excipient

Is bergamot oil listed as an inactive ingredient in FDA-approved medicines?

Some bergamot-derived materials may have prior use in regulated products, but FDA acceptability depends on the specific preparation, route, concentration, and formulation. The FDA Inactive Ingredient Database should be evaluated at the exact ingredient and dosage-form level.[3]

Can bergamot oil be used in topical pharmaceutical products?

It can be used only with careful control of phototoxic constituents and exposure conditions. Furanocoumarin content, ultraviolet exposure, product concentration, and labeling requirements are central to the safety assessment.

Is bergamot a compendial USP excipient?

Bergamot is not generally treated as a broad, interchangeable compendial excipient like microcrystalline cellulose, lactose, or magnesium stearate. Manufacturers must usually rely on product-specific specifications and supplier qualification.

Does bergamot interact with statins and other medicines?

Bergamot preparations may contain constituents capable of affecting drug-metabolizing enzymes or transporters. The interaction profile depends on the extract composition and dose, so pharmaceutical products require product-specific assessment rather than reliance on the common name alone.

What would increase the value of the bergamot excipient market?

The strongest catalysts would be an FDA-recognized standardized specification, broader use in approved oral medicines, validated low-furanocoumarin technologies, clinical evidence for defined extracts, and long-term supply agreements with pharmaceutical manufacturers.

References

1. Dugo, G., & Mondello, L. (Eds.). (2011). Citrus oils: Composition, advanced analytical techniques, contaminants, and biological activity. CRC Press.
2. Naganuma, M., et al. (1985). Mechanism of bergamot oil phototoxicity. Toxicology and Applied Pharmacology, 80(1), 87-94.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
4. European Parliament and Council of the European Union. (2008). Regulation (EC) No. 1334/2008 on flavorings and certain food ingredients with flavoring properties for use in and on foods.
5. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.